Ann M. Lowe

1.8k total citations · 1 hit paper
11 papers, 1.4k citations indexed

About

Ann M. Lowe is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Ann M. Lowe has authored 11 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Ann M. Lowe's work include Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Myeloid Leukemia Research (2 papers). Ann M. Lowe is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Acute Myeloid Leukemia Research (2 papers). Ann M. Lowe collaborates with scholars based in United States, United Kingdom and Portugal. Ann M. Lowe's co-authors include Larry D. Cripe, Ann S. LaCasce, John P. Leonard, Margaret A. Shipp, Jeff P. Sharman, Rajni Sinha, Julia Schaefer-Cutillo, Sven de Vos, John Sweetenham and Ronald Levy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Pediatrics.

In The Last Decade

Ann M. Lowe

11 papers receiving 1.4k citations

Hit Papers

Inhibition of Syk with fostamatinib disodium has signific... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    2009 590 citations Jonathan W. Friedberg, Jeff P. Sharman et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann M. Lowe United States 9 579 491 414 293 273 11 1.4k
Ellen D. McPhail United States 23 558 1.0× 798 1.6× 724 1.7× 191 0.7× 80 0.3× 110 1.7k
Pamela Drullinsky United States 17 294 0.5× 180 0.4× 525 1.3× 361 1.2× 220 0.8× 57 1.3k
Bernardo Garicochea Brazil 19 287 0.5× 203 0.4× 410 1.0× 40 0.1× 210 0.8× 67 1.4k
M Shiota Japan 22 324 0.6× 1.2k 2.4× 441 1.1× 91 0.3× 105 0.4× 32 1.9k
Kimberly Hayes United States 19 753 1.3× 394 0.8× 428 1.0× 63 0.2× 114 0.4× 38 1.5k
Tammy Price-Troska United States 17 522 0.9× 481 1.0× 835 2.0× 63 0.2× 157 0.6× 34 1.6k
Nicola M. Tomas Germany 15 155 0.3× 492 1.0× 349 0.8× 106 0.4× 87 0.3× 30 1.5k
Christoph Thorns Germany 25 300 0.5× 716 1.5× 661 1.6× 53 0.2× 454 1.7× 83 1.8k
Jan B. Egan United States 16 216 0.4× 436 0.9× 868 2.1× 44 0.2× 272 1.0× 34 1.6k
Michele Massimino Italy 22 339 0.6× 128 0.3× 496 1.2× 38 0.1× 249 0.9× 64 1.2k

Countries citing papers authored by Ann M. Lowe

Since Specialization
Citations

This map shows the geographic impact of Ann M. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann M. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann M. Lowe more than expected).

Fields of papers citing papers by Ann M. Lowe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann M. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann M. Lowe. The network helps show where Ann M. Lowe may publish in the future.

Co-authorship network of co-authors of Ann M. Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Ann M. Lowe. A scholar is included among the top collaborators of Ann M. Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann M. Lowe. Ann M. Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Courtney, Kevin D., Jeffrey R. Infante, Elaine T. Lam, et al.. (2017). Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 36(9). 867–874. 296 indexed citations
3.
Jaglowski, Samantha, Jeffrey A. Jones, Joseph M. Flynn, et al.. (2012). A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.. Journal of Clinical Oncology. 30(15_suppl). 6508–6508. 51 indexed citations
4.
Ramanathan, Ramesh K., Joe Stephenson, Glen J. Weiss, et al.. (2011). A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Investigational New Drugs. 30(4). 1591–1596. 32 indexed citations
5.
Tibes, Raoul, G. S. Falchook, Daniel D. Von Hoff, et al.. (2010). Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.. Journal of Clinical Oncology. 28(15_suppl). 3076–3076. 35 indexed citations
6.
Friedberg, Jonathan W., Jeff P. Sharman, John Sweetenham, et al.. (2009). Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115(13). 2578–2585. 590 indexed citations breakdown →
7.
8.
9.
10.
Sokol, Lubomir, Larry D. Cripe, Hagop M. Kantarjian, et al.. (2006). Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).. Blood. 108(11). 2657–2657. 2 indexed citations
11.
Siegel, David S., A. Krishnan, Sagar Lonial, et al.. (2006). Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).. Blood. 108(11). 3580–3580. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen D. McPhail Breakdown of academic impact, for papers by Pamela Drullinsky Breakdown of academic impact, for papers by Bernardo Garicochea Breakdown of academic impact, for papers by M Shiota Breakdown of academic impact, for papers by Kimberly Hayes Breakdown of academic impact, for papers by Tammy Price-Troska Breakdown of academic impact, for papers by Nicola M. Tomas Breakdown of academic impact, for papers by Christoph Thorns Breakdown of academic impact, for papers by Jan B. Egan Breakdown of academic impact, for papers by Michele Massimino
Rankless by CCL
2026